Italia markets open in 4 hours 43 minutes

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,3700-0,0100 (-0,42%)
Alla chiusura: 04:00PM EDT
2,3300 -0,04 (-1,69%)
Dopo ore: 04:28PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,3800
Aperto2,4000
Denaro2,2900 x 100
Lettera2,4200 x 100
Min-Max giorno2,3300 - 2,4700
Intervallo di 52 settimane1,7800 - 5,1400
Volume322.914
Media Volume186.117
Capitalizzazione234,39M
Beta (5 anni mensile)1,01
Rapporto PE (ttm)N/D
EPS (ttm)-0,7000
Prossima data utili26 apr 2024 - 30 apr 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A10,48
  • GlobeNewswire

    AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

    AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will present a corporate overview and participate in one-on-one investor meetings during the Jefferies 2023 CNS & Neuro Summit, taking place in-person in New York City on October 11-12, 2023. AC Immune’s cor

  • GlobeNewswire

    AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

    AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will present a corporate overview and participate in one-on-one investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference, taking place virtually and in-perso

  • GlobeNewswire

    AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

    AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer’s disease (AD)Enrollment in ongoing Phase 1b/2 ABATE study of ACI-24.060 in AD and Down syndrome (DS) is on track and expanding to sites in USA following IND clearance, dosed first individual with DSNext interim safety and immunogenicity data from AD and DS cohorts in ABATE expected in H2 2023R